National Cancer Institute



13th Annual Innovative Molecular Analysis Technologies (IMAT) Program Principal Investigators (PI) Meeting

November 27-28, 2012

The Methodist Hospital Research Institute
Houston, Texas

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Program Overview

Welcome to the 13th Annual Innovative Molecular Analysis Technologies (IMAT) Program Principal Investigators (PI) Meeting. As many of you already know, this annual meeting is organized to address two important aims of the IMAT program: (1) to provide NCI program staff a chance to interact directly with PIs and receive an update on progress to date with supported research and (2) to provide an opportunity for interactions and exchange of ideas among meeting participants. This latter aim is a critical opportunity for sparking potentially transformative project collaborations, receiving critical feedback and guidance from the community, as well as for fostering dissemination of the exciting technologies emerging from IMAT-supported researchers.

The overarching theme for this year's meeting is to *emphasize the importance of engaging technology end-users*, and so the meeting includes various mechanisms for facilitating that communication. To that end, each of the speaker sessions will be chaired by a prominent researcher or clinician engaged in a field relevant to the session topic. They have been asked to provide a brief overview of the various basic and/or clinical research challenges associated with the topic that represent unmet opportunities for innovative technology solutions. Further, our IMAT success story overviews a dissemination path that did not require commercialization of the platform to have a significant impact on cancer research.

As there are more exciting active research projects in the IMAT portfolio than we could possibly allow sufficient speaking time for, we are repeating the "Poster Highlights" session that was piloted last year, in which a number of investigators will give short overview talks on their research posters. An additional change to this year's meeting spurred by our theme is to open the meeting on the afternoon of the first day to all interested local area researchers and clinicians, which will overlap with the Poster Highlights session, and the subsequent poster session in the atrium.

In addition to the agenda and presentation abstracts, a list of resources and funding opportunities that we thought might be of interest to participants are included toward the back of the book. On behalf of the NCI program staff and everyone involved in the planning for this meeting, I thank you for your participation, your interest, and the important work you all do to assist in our collective mission against cancer. I look forward to an exciting and productive meeting.

Sincerely,

Tony Dickherber, Ph.D.
Program Director
Center for Strategic Scientific Initiatives
Office of the Director
National Cancer Institute

Agenda

Day 1: Tuesday, November 27

8:00 a.m. - 8:45 a.m. Registration and Continental Breakfast

Poster Session Setup

8:45 a.m. - 9:00 a.m. Welcome *Auditorium*
Tony Dickherber, Ph.D., Program Director
Innovative Molecular Analysis Technologies Program
National Cancer Institute, NIH

9:00 a.m. - 10:10 a.m. Panel Session: Novel Biosensors I
Chair: Steven Shen, M.D., Ph.D.
The Methodist Hospital Research Institute

9:10 a.m. - 9:30 a.m. *Measuring Kinase Activity in Intact Cells Using Surface-Enhanced Raman Spectroscopy Nanosensors*
Alyssa Garrelts, Ph.D.
Purdue University

9:30 a.m. - 9:50 a.m. *Nanoelectrode and Nanofluidic-Based Assay of Mitochondria Membrane Potential and Apoptosis*
Peter J. Burke, Ph.D.
University of California, Irvine

9:50 a.m. - 10:10 a.m. *Multiplex Cancer Cell Purification With Magnetic Sifters*
Shan X. Wang, Ph.D.
Stanford University

10:10 a.m. - 10:30 a.m. Break

10:30 a.m. - 12 noon Panel Session: Novel Biosensors II
Chair: Rebecca R. Richards-Kortum, Ph.D.
Rice University

10:40 a.m. - 11:00 a.m. *Quantifying RNA-Protein Interactions In Situ Using Modified-MTRIPs and Proximity Ligation*
Philip J. Santangelo, Ph.D.
Georgia Institute of Technology and Emory University

11:00 a.m. - 11:20 a.m. *Highly Multiplexed, Spatially Delineated Molecular Imaging in Cancer*
Michael R. Diehl, Ph.D.
Rice University

11:20 a.m. - 11:40 a.m. *An Integrated Platform for Quantifying Gene Expression in Co-Cultured Cells*
David J. Beebe, Ph.D.
University of Wisconsin

11:40 a.m. - 12 noon — *Rapid and Sensitive Multiplex Sequencing of Actionable Cancer Genes in Clinical Samples*
Stephen Salipante, M.D., Ph.D.
University of Washington

12 noon - 1:00 p.m. — Lunch (on your own)

1:00 p.m. - 2:00 p.m. — Success Story: Collaboration Versus Commercialization to Disseminate Your Technology
William C. Hahn, M.D., Ph.D.
Dana-Farber Cancer Institute

David E. Hill, Ph.D.
Dana-Farber Cancer Institute

2:00 p.m. - 3:50 p.m. — Poster Highlights Session

Activatable BRET Probes for MMP Enzymatic Activity Detection
Jianghong Rao, Ph.D.
Stanford University

Development of a Methylation-Based Diagnostic Assay for Malignant Melanoma: Defining the Factors Affecting Marker Selection and Assay Performance
Sharon N. Edmiston
The University of North Carolina at Chapel Hill

FRET-Based Biosensors to Monitor Redox in Cell Cycle Regulation
Vladimir Kolossov, Ph.D.
University of Illinois, Urbana-Champaign

Microfluidic Sorting of Blood Cells for SPR and Fluorescence Analysis
Nathaniel C. Cady, Ph.D.
University at Albany

Application of an Innovative Technology to Develop Low-Toxicity Kinase Inhibitors
Xiang Li, Ph.D.
University of Maryland, Baltimore County

Multiple Reaction Monitoring to Profile Biosensor Phosphorylation in Leukemia
Laurie L. Parker, Ph.D
Purdue University

Probing Cancer Cell Chemoinvasion Strategies Using 3D Microfluidic Models
Mingming Wu, Ph.D.
Cornell University

Specific and Reversible Binding of DNA Nanoparticles to Cancer Cells
Bradley T. Messmer, Ph.D.
University of California, San Diego

2D-PCR for Spatially Mapping Gene Changes in Tumor Sections
Daniel Gowetski, Ph.D.
University of Maryland

Discovery Platform for Cancer Antigens
Kevin Claffey, Ph.D.
University of Connecticut Health Center

Digital Analysis of Proteins Through End Sequencing (DAPES)
Tom Cohen, Ph.D.
Washington University in St. Louis

Molecular Diagnostic Tests to Augment Cytomorphologic Diagnosis of Lung Cancer
James C. Willey
University of Toledo

Method for Detection of Secreted Proteins in Single-Cell Assays
Henryk Szmacinski, Ph.D.
University of Maryland

3:50 p.m. - 6:00 p.m.	Poster Session	*First Floor Lobby*

Day 2: Wednesday, November 28

8:00 a.m. - 8:15 a.m. — Recap of Day One and Overview of Day Two — *Auditorium*
Tony Dickherber, Ph.D.
Innovative Molecular Analysis Technologies Program
National Cancer Institute, NIH

8:15 a.m. - 8:45 a.m. — Host Welcome
Mauro Ferrari, Ph.D.
The Methodist Hospital Research Institute

8:45 a.m. - 9:30 a.m. — Keynote Address
Joshua LaBaer, M.D., Ph.D.
The Biodesign Institute
Arizona State University

9:30 a.m. - 10:40 a.m. — Panel Session: Pathway Tools - 1
Chair: TBD

- 9:40 a.m. - 10:00 a.m. — *VEC³-Valve Enabled Cell Co-Culture Platforms for Cancer Biology Study*
  Deyu Li, Ph.D.
  Vanderbilt University
- 10:00 a.m. - 10:20 a.m. — *Translational Control Analysis by Translationally Active RNA Capture/Microarray Analysis (TrIP-Chip)*
  Jingfang Ju, Ph.D.
  Stony Brook University
- 10:20 a.m. - 10:40 a.m. — *Scanning Correlation Microscopy Methods for Quantifying DNA Repair Kinetics*
  Georgios Alexandrakis, Ph.D.
  The University of Texas at Arlington

10:40 a.m. - 11:00 a.m. — Break

11:00 a.m. - 12:30 p.m. — Panel Session: Biomarker Preservation and Discovery
Chair: Ignacio Wistuba, M.D.
The University of Texas MD Anderson Cancer Center

- 11:10 a.m. - 11:30 a.m. — *Genome-Scale DNA Methylation Profiling in the Developing Colon and the Impact of Diet*
  Lanlan Shen, M.D., Ph.D.
  Baylor College of Medicine
- 11:30 a.m. - 11:50 a.m. — *Detection of Low-Prevalence Mutations in Solid Tumors via Ultra-Deep Targeted Sequencing*
  Olivier Harismendy, Ph.D.
  University of California, San Diego

11:50 a.m. - 12:10 p.m. *Tissue Is Alive: Preserving Biomolecules and Tissue Morphology in Clinical Trial Samples*
Lance A. Liotta, M.D., Ph.D.
George Mason University

12:10 p.m. - 12:30 p.m. *Sentinel RNAs as a Measure of mRNA Integrity in Clinical Biospecimens*
Curt H. Hagedorn, M.D.
University of Utah

12:30 p.m. - 1:30 p.m. Lunch (on your own)

1:30 p.m. - 2:40 p.m. Panel Session: Pathway Tools - 2
Chair: Stephen Wong, Ph.D.
The Methodist Hospital Research Institute

1:40 p.m. - 2:00 p.m. *Development and Application of Novel Glycan-Specific Reagents to Facilitate Early Detection of Epithelial Ovarian Cancer*
David C. Muddiman, Ph.D.
North Carolina State University

2:00 p.m. - 2:20 p.m. *Targeted Selection, Sequencing, and Analysis of Human Telomere and Subtelomere DNA in Cancer*
Harold C. Riethman, Ph.D.
The Wistar Institute

2:20 p.m. - 2:40 p.m. *Application of Next-Generation Sequencing to Cancer Epigenomics*
Huidong Shi, Ph.D.
Georgia Health Sciences University

2:40 p.m. - 3:00 p.m. Break

3:00 p.m. - 4:50 p.m. Panel Session: Technologies to Assist With Drug Screening and Delivery
Chair: Melissa D. Landis, Ph.D.
The Methodist Hospital Research Institute

3:10 p.m. - 3:30 p.m. *Magnetorotation: A Rapid Assay for Single Cell Drug Sensitivity of Cancer Cells*
Raoul Kopelman, Ph.D.
University of Michigan

3:30 p.m. - 3:50 p.m. *Scaffolds for Delivering Deoxycytidine Kinase to HER2 Positive Cancer Cells*
Brian K. Kay, Ph.D.
University of Illinois at Chicago

3:50 p.m. - 4:10 p.m. *384-Well Cell Migration Assay Suitable for High-Throughput Screening (HTS) of Chemical Libraries for Cancer Therapeutics*
Andreas Vogt, Ph.D.
University of Pittsburgh Drug Discovery Institute

4:10 p.m. - 4:30 p.m.	*Hyperspectral and Structural Microscopy Platform for Therapy of Resistant Cancer* Conor L. Evans, Ph.D. Harvard University
4:30 p.m. - 4:50 p.m.	*Ultra-Throughput Multiple Reaction Monitoring Mass Spectrometry for Large-Scale Cancer Biomarker Validation* Xudong Yao, Ph.D. University of Connecticut
4:50 p.m. - 5:00 p.m.	Closing Remarks and Adjournment Tony Dickherber, Ph.D. Innovative Molecular Analysis Technologies Program National Cancer Institute, NIH

Speaker Abstracts

*Abstracts that are also part of the poster session.

Poster Abstracts

Poster Number	Presenter	Abstract Title	Page Number
20	Sarah Blair	Hollow Perfluoropentane Filled Silica Nano and Microparticles for Breast Conservation Therapy	75
21	Eugene Kandel	Improved Insertional Mutagenesis for Molecular Analysis of Cancer	76
22	Daniel Chiu	Isolation and Analysis of Circulating Tumor Cells	77
23	Raoul Kopelman	Magnetorotation: A Rapid Assay for Single-Cell Drug Sensitivity of Cancer Cells	78
24	Henryk Szmacinski	Method for Detection of Secreted Proteins in Single-Cell Assays	79
25	Yin-Yuan Mo	Methods of Systematic microRNA Target Validation and Identification	80
26	Nathaniel Cady	Microfluidic Sorting of Blood Cells for SPR and Fluorescence Analysis	81
27	James Willey	Molecular Diagnostic Tests to Augment Cytomorphologic Diagnosis of Lung Cancer	82
28	Shan X. Wang	Multiplex Cancer Cell Purification With Magnetic Sifters	83
29	Laurie Parker	Multiple Reaction Monitoring to Profile Biosensor Phosphorylation in Leukemia	84
30	Jason Held	OxMRM: Quantifying Oxidation of Endogenous Redox-Sensitive Cysteines In Targeted Proteins Using Multiple Reaction Monitoring	86
31	Anthony DeCaprio	Platform for High-Throughput Analysis of Protein Adducts for Carcinogen Exposure Assessment	87
32	Mingming Wu	Probing Cancer Cell Chemoinvasion Strategies using 3D Microfluidic Models	89
33	Brian Hrudka	ProCure System	90
34	Songping Huang	Prussian Blue Nanoparticles as Cellular T1 MRI Contrast Agents	91
35	Keqi Tang	Pushing the Limit of Sensitivity for LC-MRM MS Quantification of Low-Abundance Protein Biomarkers	92
36	Margaret Gulley	Screening of Novel Small Molecule Candidates to Augment Formalin Fixation	93
37	Curt Hagedorn	Sentinel RNAs as a Measure of mRNA Integrity in Clinical Biospecimens	94
38	Bradley Messmer	Specific and Reversible Binding of DNA Nanoparticles to Cancer Cells	95
39	Thomas M. Blomquist	Standardized Mixtures of Internal Standards in Quantitative Sequencing Enables Inter-laboratory and Inter-platform Concordance and Reduces Costs by Log-Order Magnitudes	96

Poster Number	Presenter	Abstract Title	Page Number
40	Rui Sousa	Successful Construction and Validation of Fluorescent Sensors for Monitoring GTP Levels in Living Cells	97
41	Matthew Levy	Targeting Cancer Cells With Functionalized Nanoparticle Libraries	98
42	G. Mike Makrigiorgos	Temperature-Tolerant COLD-PCR Enables Mutation Enrichment Using a Single Cycling Protocol for Diverse DNA Sequences	99
43	Lance Liotta	Tissue Is Alive: Preserving Biomolecules and Tissue Morphology in Clinical Trial Samples	100
44	Xudong Yao	Ultra-Throughput Multiple Reaction Monitoring Mass Spectrometry for Large-Scale Cancer Biomarker Validation	101
45	David Beebe	Understanding Stromal-Cancer Cell Interactions via a Microscale 3D Model of DCIS	102
46	John McDonald	Use of Nanogels to Target Delivery of siRNA to Cancer Cells in Mice	104
47	Kenneth Greis	Validation of MALDI-MS-Based Inhibitor Screening Technologies for Cancer Targets	105
48	Deyu Li	VEC^3-Valve Enabled Cell Co-Culture Platforms for Cancer Biology Study	107
49	Dale Larson	Development of a Nanoscale Calorimeter	108

Resources and Funding Opportunities

Resources

- TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) provides a platform for researchers to search, download, and analyze datasets generated by TCGA. It contains clinical information, genomic characterization data, and high-throughput sequencing analysis of the tumor genomes.
- NCI Proteomics Data Portal (https://cptac-data-portal.georgetown.edu/cptacPublic/) provides proteomics datasets of breast, ovarian, and tumor tissue that have also been genomically characterized by TCGA datasets.
- The Antibody Characterization Laboratory (http://Antibodies.cancer.gov) provides access to a large number of reagents and accompanying characterization data. Antigens and antibodies are expressed, purified, and characterized using standard operating procedures, with all accompanying protocols and data.
- NCI Best Practices for Biospecimen Resources guiding principles define state-of-the-science biospecimen resource practices, promote biospecimen and data quality, and support adherence to ethical and legal requirements (http://biospecimens.cancer.gov/practices/default.asp).

Funding Opportunities

- Innovative Molecular Analysis Technologies (IMAT) reissuance
  - Early-stage innovative molecular analysis technologies for cancer research (R21, up to 3 years and $500k in direct costs) – RFA-CA-13-001
  - Advanced development and validation of emerging molecular analysis technologies for cancer research (R33, up to 3 years and $900k in direct costs) – RFA-CA-13-002
  - Early-stage innovative technologies for biospecimen science (R21, up to 3 years and $500k in direct costs) – RFA-CA-13-003
  - Advanced development and validation of emerging technologies for biospecimen science(R33, up to 3 years and $900k in direct costs) – RFA-CA-13-004

- NCI Provocative Questions (PQ) initiative (http://provocativequestions.nci.nih.gov/), to support research projects designed to use sound and innovative research strategies to solve specific problems and paradoxes in cancer research
  - Group A covered by RFA-CA-12-015 (R01) and RFA-CA-12-016 (R21) that generally relates to cancer prevention and risk
  - Group B covered by RFA-CA-12-017 (R01) and RFA-CA-12-018 (R21) that generally relates to mechanisms of tumor development or recurrence
  - Group C covered by RFA-CA-12-019 (R01) and RFA-CA-12-020 (R21) that generally relates to cancer detection, diagnosis, and prognosis
  - Group D covered by RFA-CA-12-021 (R01) and RFA-CA-12-022 (R21) that generally relates to cancer therapy and outcomes

- Informatics Technology for Cancer Research (ITCR) program (http://itcr.nci.nih.gov)
  - Early-stage development including initial development (prototyping) and modification of existing methods for new applications: collaborate with NCI grantees and target naïve users for up to $150k DC/yr for 2 years - PAR-12-286[R01 supplement], PAR-12-290[P01 supplement], PAR-12-289[U01 supplement]
  - Early-stage development (U01) at the prototyping and hardening stages, for up to $250k DC/year for 3 years - PAR-12-288
  - Advanced development (U24) at the enhancement, dissemination, and maintenance stages: target both naïve users and power users, for up to $500k DC/year for 5 years - PAR-12-287

NIH...Turning Discovery into Health